The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.00
Bid: 112.00
Ask: 113.00
Change: 0.50 (0.45%)
Spread: 1.00 (0.893%)
Open: 109.50
High: 112.00
Low: 109.50
Prev. Close: 111.50
LIT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Litigation Finance Agreement

16 May 2022 07:00

RNS Number : 5288L
Litigation Capital Management Ltd
16 May 2022
 

16 May 2022

 

Litigation Capital Management Limited

("LCM" or the "Company")

 

Litigation Finance Agreement for new representative claim against Google and DeepMind Technologies

 

Litigation Capital Management Limited (AIM:LIT), an alternative asset manager specialising in dispute financing solutions internationally, announces that it has entered into a litigation finance agreement for a new representative claim.

The finance agreement is to fund a new representative action in the High Court of Justice of England & Wales brought on behalf of up to 1.6 million individuals against Google and DeepMind Technologies for the unlawful use of patients' confidential medical records.

The claim is for the misuse of private information and arises out of an arrangement formed in 2015 between Google and DeepMind and the Royal Free London NHS Foundation Trust. The tech companies obtained and used a substantial number of confidential and private medical records without patients' knowledge or consent.

This representative claim being brought by Mishcon de Reya, provides access to justice and a means of compensation which would not have been viable on an individual basis due to the cost of the litigation process. Not only does it provide a means of redress to those affected by the misuse of their private and confidential medical records but this is also a significant claim for LCM to support and fund.

 

Patrick Moloney, CEO of LCM, commented: "LCM has a long and deep experience in funding large scale actions, many of which would not be possible without litigation funding. As pioneers of the industry, we are well-placed to support the claim in this action."

 

 

Enquiries

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

Alma PR

Tel: 020 3405 0205

Justine James

LCM@almapr.co.uk

Kieran Breheny

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) is an alternative asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

 

LCM has an unparalleled track record driven by disciplined project selection and robust risk management.

 

Currently headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

 

www.lcmfinance.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRGPUCPAUPPGCA
Date   Source Headline
23rd Aug 20227:00 amRNSNotice of Results
15th Jul 20228:22 amRNSDirector/PDMR Shareholding
8th Jul 20227:00 amRNSMarket Update
16th May 20227:00 amRNSLitigation Finance Agreement
4th May 202210:15 amRNSDirector/PDMR Shareholding
25th Apr 20229:30 amRNSDirector/PDMR Shareholding
11th Apr 202211:10 amRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSInterim Results
14th Mar 202210:30 amRNSHolding(s) in Company
15th Feb 20227:00 amRNSNotice of Results
14th Feb 20227:00 amRNSMary Gangemi Appointed to the Board
7th Feb 202210:30 amRNSDirector/PDMR Shareholding
1st Feb 202212:45 pmRNSDirector/PDMR Shareholding
4th Jan 20223:58 pmRNSHolding(s) in Company
29th Dec 20214:10 pmRNSDirector/PDMR Shareholding
17th Dec 20217:00 amRNSBoard change
10th Dec 202112:30 pmRNSIssue of Equity and Total Voting Rights
18th Nov 20217:00 amRNSResult of AGM
4th Nov 20217:00 amRNSSuccessful Award in LCIA International Arbitration
29th Oct 20211:24 pmRNSExercise of Options, Equity Issue, Director/PDMR
29th Oct 20211:00 pmRNSIncentive Awards
25th Oct 20217:00 amRNSNotice of AGM
18th Oct 202111:15 amRNSIssue of Equity and Total Voting Rights
14th Oct 20217:00 amRNSLCM Global Alternative Returns Fund II
22nd Sep 202111:20 amRNSHolding(s) in Company
21st Sep 20217:00 amRNSFinal Results 2021
31st Aug 20217:00 amRNSNotice of Results
11th Aug 20217:07 amRNSSuccessful judgment in Australian investment
19th Jul 20217:00 amRNSMarket Update
6th Jul 20217:00 amRNSNew Litigation Finance Agreement
23rd Jun 20217:00 amRNSComet Group liquidation claim
21st Jun 20217:21 amRNSJudgment in New Zealand Investment
27th May 20217:00 amRNSInvestor Presentation
19th May 20217:18 amRNSLitigation Finance Agreement with Carillion
4th May 202112:09 pmRNSHolding(s) in Company
14th Apr 20214:41 pmRNSSecond Price Monitoring Extn
14th Apr 20214:36 pmRNSPrice Monitoring Extension
16th Mar 20217:00 amRNSInterim Results
10th Mar 20216:07 pmRNSIssue of Equity and Total Voting Rights
10th Mar 20215:53 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSRetail Investor Presentation
22nd Feb 20217:00 amRNSNew US$50m Credit Facility
18th Feb 20212:30 pmRNSHolding(s) in Company
17th Feb 20217:00 amRNSNotice of Results
12th Feb 20215:13 pmRNSHolding(s) in Company
7th Jan 202111:20 amRNSHolding(s) in Company
17th Dec 202012:17 pmRNSHolding(s) in Company
19th Nov 20207:00 amRNSResult of AGM
28th Oct 20207:00 amRNSNotice of Annual General Meeting
15th Oct 202010:30 amRNSIncentive Awards

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.